BRISTOL-MYERS SQUIBBDL-10/ US1101221083 /
2024-06-14 5:51:52 PM | Chg. +0.335 | Volume | Bid6:05:04 PM | Ask6:05:04 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
39.035EUR | +0.87% | 9,470 Turnover: 366,967.610 |
38.900Bid Size: 1,050 | 39.060Ask Size: 1,050 | 78.68 bill.EUR | - | - |
GlobeNewswire
2:00 PM
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored...
GlobeNewswire
06-11
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
06-11
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
GlobeNewswire
06-10
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
GlobeNewswire
05-31
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting P...
GlobeNewswire
05-30
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
05-23
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retire...
GlobeNewswire
05-23
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Pr...
GlobeNewswire
05-14
Firefly Neuroscience, an AI-Driven Brain Health Company, Appoints Healthcare-Industry Executive, Dav...
GlobeNewswire
05-14
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
05-13
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire
05-08
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Immunocore reports first quarter financial results and provides a business update
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...